Crinetics Pharmaceuticals

Forecast & Rating14 analysts currently cover Crinetics Pharmaceuticals, with about 7.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $85.50, about 0.6% upside from the current price of $84.95. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 46.4% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Crinetics Pharmaceuticals's outlook. Data as of Sep 1, 2026; for reference only and not investment advice.